CSL (Other OTC: CMXHF) has declared, under its dividend policy, a semi-annual cash dividend in the amount of $1.62 per common share. That signifies an annualized amount of $3.24 per share.

Summer Sale - Claim 70% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

The dividend will be payable on 10/02/2026, to holders of record at the close of business on 09/10/2026.

CMXHF has a dividend yield of 2.62%.

According to the 9 analysts who have given a rating to CSL in the past three months, the analyst consensus rating on CMXHF is a Moderate Buy.

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.

Visit Tipranks’ unique Dividend Calendar to explore more dividend announcement dates and investment opportunities today!